has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties …
Current Pharmaceutical Design, 2018
[2] Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual …
Journal of Pharmaceutical Investigation, 2018
[3] Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of …
Chemical biology & drug design, 2017
[4] Gemcitabine‐(5'‐phosphoramidate)‐[anti‐IGF‐1R]: Molecular Design, Synthetic Organic Chemistry Reactions, and Antineoplastic Cytotoxic Potency in Populations of …
Chemical biology & drug design, 2016
[5] Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against …
Drug design, development and therapy, 2016
[6] Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against …
Drug design, development and therapy, 2016
[7] Fludarabine-(C2-methylhydroxyphosphoramide)-[anti-IGF-1R]: Synthesis and Selectively “Targeted” Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)
Journal of pharmaceutics & drug delivery research, 2015
[8] Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se] …
Journal of cancer therapy, 2015
[9] Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se] …
Journal of cancer therapy, 2015
[10] Fludarabine-(C2-methylhydroxyphosphoramide)-[anti-IGF-1R]: synthesis and selectively “targeted” anti-neoplastic cytotoxicity against pulmonary …
Journal of pharmaceutics & drug delivery research, 2015
[11] Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against …
Medicinal chemistry, 2014
[12] Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine
Journal of Cancer Therapy, 2014
[13] Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole
Journal of cancer research and therapeutic oncology, 2014
[14] Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma
Journal of Clinical & Experimental Oncology, 2013
[15] Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3)
Medicinal Chemistry, 2013
[16] Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary …
Journal of clinical & experimental oncology, 2013
[17] Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-HER2/neu] in combination with Griseofulvin against chemotherapeutic-resistant mammary …
Medicinal chemistry, 2013
[18] Gemcitabine-(C4-amide)-[anti-HER2/neu] anti-neoplastic cytotoxicity in dual combination with mebendazole against chemotherapeutic-resistant mammary …
Journal of clinical & experimental oncology, 2013
[19] Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-HER2/neu] in combination with Griseofulvin against chemotherapeutic-resistant mammary …
Medicinal chemistry, 2013